The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Defining Optimal Therapy for Muscle Invasive Bladder Cancer
Abstract
PURPOSE: We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy. MATERIALS AND METHODS: We reviewed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. We analyzed all cohort, phase II and randomized phase III studies providing level 1 to 3 evidence impacting survival. RESULTS: Cisplatin based chemotherapy combined with high quality radical cystectomy and complete pelvic lymph node dissection improves survival over that of cystectomy alone. Surgery quality is an important predictor of survival even in patients receiving chemotherapy. Neoadjuvant chemotherapy is favored over adjuvant chemotherapy because it is better tolerated and more patients are able to receive effective therapy before rather than after surgery. CONCLUSIONS: Neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection is the optimal curative strategy in most patients presenting with muscle invasive bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence based medicine: what it is and what it isn't
Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, R. B., & Richardson, W. S. (1996) · BMJ · doi:10.1136/bmj.312.7023.71 · Cited by 15,769
Cited by
Raman, J. D., Messer, J., Sielatycki, J. A., & Hollenbeak, C. S. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.09675.x · Cited by 364
Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer
Catto, J. W. F., Miah, S., Owen, H. C., Bryant, H., Myers, K., Dudziec, E., Larré, S., Milo, M., Rehman, I., Rosario, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0744 · Cited by 329
MicroRNA-34a: a potential therapeutic target in human cancer
Li, X. J., Ren, Z. J., & Tang, J. H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.270 · Cited by 287
Boorjian, S. A., Sheinin, Y., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270
Metadata
- Authors
- Herr, H. W., Dotan, Z., Donat, S. M., & Bajorin, D. F.
- Venue
- Journal of Urology
- Published
- 2007-02
- Volume
- 177
- Issue
- 2
- Pages
- 437-443
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2126069168
- Cited by
- 226
- References
- 1
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Defining Optimal Therapy for Muscle Invasive Bladder Cancer. https://app.cochat.ai/papers/10.1016/j.juro.2006.09.027
- The paper
- Herr, H. W., Dotan, Z., Donat, S. M., & Bajorin, D. F. (2007). Defining Optimal Therapy for Muscle Invasive Bladder Cancer. Journal of Urology. https://doi.org/10.1016/j.juro.2006.09.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
